| Immune checkpoint inhibitors in organ transplant patients AS Kittai, H Oldham, J Cetnar, M Taylor Journal of Immunotherapy 40 (7), 277-281, 2017 | 149 | 2017 |
| Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib MJ Gordon, M Churnetski, H Alqahtani, X Rivera, A Kittai, SM Amrock, ... Cancer 124 (15), 3192-3200, 2018 | 80 | 2018 |
| Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome AS Kittai, DA Bond, B William, A Saad, S Penza, Y Efebera, K Larkin, ... Blood Advances 4 (19), 4648-4652, 2020 | 68 | 2020 |
| Targeting ubiquitin-activating enzyme induces ER stress–mediated apoptosis in B-cell lymphoma cells S Best, T Hashiguchi, A Kittai, N Bruss, C Paiva, C Okada, T Liu, A Berger, ... Blood advances 3 (1), 51-62, 2019 | 47 | 2019 |
| The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib AS Kittai, C Miller, D Goldstein, Y Huang, LV Abruzzo, K Beckwith, ... Blood, The Journal of the American Society of Hematology 138 (23), 2372-2382, 2021 | 44 | 2021 |
| Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma J Zurko, J Ramdial, M Shadman, S Ahmed, A Szabo, L Iovino, AA Tomas, ... Haematologica 108 (1), 98, 2023 | 42 | 2023 |
| Comorbidities predict inferior survival in patients receiving chimeric antigen receptor T cell therapy for diffuse large B cell lymphoma: a multicenter analysis AS Kittai, Y Huang, M Gordon, N Denlinger, A Mian, L Fitzgerald, J Bishop, ... Transplantation and Cellular Therapy 27 (1), 46-52, 2021 | 39 | 2021 |
| Ventricular arrhythmias and sudden death events following acalabrutinib initiation SA Bhat, J Gambril, L Azali, ST Chen, L Rosen, M Palettas, TE Wiczer, ... Blood, The Journal of the American Society of Hematology 140 (20), 2142-2145, 2022 | 38 | 2022 |
| Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells S Best, V Lam, T Liu, N Bruss, A Kittai, OV Danilova, S Murray, A Berger, ... Leukemia 35 (1), 156-168, 2021 | 32 | 2021 |
| Proteogenomics refines the molecular classification of chronic lymphocytic leukemia SA Herbst, M Vesterlund, AJ Helmboldt, R Jafari, I Siavelis, M Stahl, ... Nature Communications 13 (1), 6226, 2022 | 24 | 2022 |
| Gonadotropin--Releasing Hormone Antagonists in Prostate Cancer. AS Kittai, J Blank, JN Graff Oncology (08909091) 32 (12), 2018 | 24 | 2018 |
| Chronic lymphocytic leukemia: current concepts EM Yu, A Kittai, IA Tabbara Anticancer research 35 (10), 5149-5165, 2015 | 24 | 2015 |
| Acalabrutinib in combination with venetoclax and obinutuzumab or rituximab in patients with treatment-naïve or relapsed/refractory chronic lymphocytic leukemia JA Woyach, JS Blachly, KA Rogers, SA Bhat, MR Grever, AS Kittai, ... Blood 136, 16-18, 2020 | 18 | 2020 |
| Resistance mechanisms to targeted agents in chronic lymphocytic leukemia AS Kittai, JA Woyach The Cancer Journal 25 (6), 428-435, 2019 | 18 | 2019 |
| Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL J Zurko, I Nizamuddin, N Epperla, K David, JB Cohen, TK Moyo, T Ollila, ... Blood Advances 7 (12), 2657-2669, 2023 | 16 | 2023 |
| Cytopenias after CD19 chimeric antigen receptor T-cells (CAR-T) therapy for diffuse large B-cell lymphomas or transformed follicular lymphoma: a single institution experience A Schaefer, Y Huang, A Kittai, JE Maakaron, C Saygin, J Brammer, ... Cancer Management and Research, 8901-8906, 2021 | 16 | 2021 |
| Three-year follow-up from a phase 2 study of combination obinutuzumab, ibrutinib, and venetoclax in chronic lymphocytic leukemia KA Rogers, Y Huang, AS Ruppert, LV Abruzzo, SA Bhat, C Hoffman, ... Blood 136, 9-10, 2020 | 16 | 2020 |
| Relevance of prognostic factors in the era of targeted therapies in CLL AS Kittai, M Lunning, AV Danilov Current Hematologic Malignancy Reports 14, 302-309, 2019 | 16 | 2019 |
| A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma G Shouse, A Kaempf, MJ Gordon, A Artz, D Yashar, AM Sigmund, ... Blood Advances 7 (14), 3516-3529, 2023 | 15 | 2023 |
| Real-world outcomes of elderly patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR-T) therapy. L Fitzgerald, A Kittai, LJ Nastoupil, A Waller, CA Jacobson, A Saucier, ... Journal of Clinical Oncology 38 (15_suppl), 8039-8039, 2020 | 15 | 2020 |
Alexey V DanilovCity of Hope National Medical CenterVerified email at coh.org
